HDFC Large & Mid Cap Fund
The scheme seeks to generate long term capital appreciation/income from a portfolio, predominantly invested in equity and equity related instruments.
Growthvine rating: 4/5 — ranked #10 of 41 in category.
Fund basics
| Category | Equity: Large & Mid Cap |
|---|
| NAV | ₹322.49 (as of 2026-10-22) |
|---|
| AUM | ₹28,543 Cr |
|---|
| Expense ratio | 1.36% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Gopal Agrawal |
|---|
| Exit load | 1% for redemption within 365 days |
|---|
Performance & risk
| 5-year annualised return | 12.21% |
|---|
| Sharpe ratio | 0.36 |
|---|
| Standard deviation | 16.63% |
|---|
| Max drawdown | −39.53% |
|---|
| Alpha | 1.84 |
|---|
| Beta | 1.07 |
|---|
Over 5 years, captured 100.4% of NIFTY LargeMidcap 250's upside and 95.2% of its downside.
Market cap allocation
| Large cap | 43.7% |
|---|
| Mid cap | 39.3% |
|---|
| Small cap | 17.0% |
|---|
Concentration
| Top 5 holdings | 12.5% |
|---|
| Top 10 holdings | 19.1% |
|---|
| Total holdings | 240 |
|---|
| Index overlap | 59.0% |
|---|
| Active share | 41.0% |
|---|
Top holdings
- ICICI Bank Ltd. — 3.7%
- HDFC Bank Ltd. — 3.6%
- AXIS Bank Ltd. — 2.0%
- Bharti Airtel Ltd. — 1.8%
- State Bank Of India — 1.4%
- Gland Pharma Limited — 1.4%
- Reliance Industries Ltd — 1.4%
- Prestige Estates Projects Limited — 1.3%
- Fortis Healthcare Ltd — 1.3%
- Aurobindo Pharma Ltd. — 1.3%
Top sectors
- Banking & Financial — 18.6%
- Pharma & Biotech — 11.9%
- Automobile — 8.2%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | −7.6% | Q3 | #24 of 38 |
| 2025 | 6.1% | Q2 | #14 of 34 |
| 2024 | 19.4% | Q3 | #18 of 29 |
| 2023 | 37.7% | Q1 (Top) | #2 of 28 |
| 2022 | 8.2% | Q1 (Top) | #4 of 28 |